This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Companies may grow organically or through acquisition. Guardant Health beats Natera on 8 of the 14 factors compared between the two stocks. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Now FDA Approved. Learn about Guardant Health , including insurance benefits, retirement benefits, and vacation policy. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. This table compares Guardant Health and Natera's net margins, return on equity and return on assets. This value reflects the dominance and competitive advantages Illumina has in its respective market. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. Guardant Health has acquired the companies: Bellwether Bio, Inc. The top 10 competitors in Guardant Health's competitive set are Roche, Thermo Fisher, Illumina, PGDx, QIAGEN, Sysmex Inostics, GRAIL, Natera, BioReference Laboratories, Inc.. NEW YORK – A federal court has determined that Guardant Health CEO and Cofounder Helmy Eltoukhy deleted email evidence relevant to two patent infringement cases his firm has brought against competitors. Guardant Health beats Invitae on 10 of the 14 factors compared between the two stocks. Together they have raised over 2.9B between their estimated 271.6K employees. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. In some cases apparently high growth rates may be caused by data that weren't available in previous years. Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. Data Sources: Yahoo Finance, Illumina, Guardant Health. Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. View our full suite of financial calendars and market data tables, all for free. Export data to Excel for your own analysis. Veracyte has lower revenue, but higher earnings than Guardant Health. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. Guardant Health is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. The company's recent first-quarter results show that its business was not immune to the COVID-19 pandemic. 76.2% of Guardant Health shares are held by institutional investors. All rights reserved. This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. 76.2% of Guardant Health shares are owned by institutional investors. Founded in 2012, San Francisco’s own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardant’s shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Guardant Health (NASDAQ:GH) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better business? Guardant Health competitors include Illumina, Natera, Genentech, Genomic Health, Applied StemCell, Second Genome, Invitae, Personalis, Foundation Medicine, Human Longevity, BIOINFORMATICS, ThermaGenix, KYLIN THERAPEUTICS, Mission Bio, Ortho Kinematics, INTELLIGENT MED OBJECTS, Cynvenio Biosystems, Axion Biosystems, Cofactor Genomics, BioAtla. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Where is Guardant Health headquarters? Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. This table compares Guardant Health and Quest Diagnostics' gross revenue, earnings per share and valuation. Should You Buy the Peloton (NASDAQ: PTON) Rally? Guardant Health's main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Learn more. Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. 9.9% of Guardant Health shares are owned by insiders. This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. Returns as of 12/15/2020. © American Consumer News, LLC dba MarketBeat® 2010-2020. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Both companies have plenty of cash to operate, but Illumina commands a market valuation of $54.2 billion, nearly seven times the $7.9 billion market cap of Guardant Health. Some of the competitors of Guardant Health are Genentech, Illumina, and Genomic Health. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. Stock Advisor launched in February of 2002. Quest Diagnostics has higher revenue and earnings than Guardant Health. Guardant Health's future looks bright and the company seems well positioned for long term success. Germany's Qiagen sees solid growth in … Comparatively, 9.3% of Natera shares are held by company insiders. This table compares Guardant Health and Veracyte's net margins, return on equity and return on assets. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. Follow a manual added link. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Want to see which stocks are moving? Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. 9.9% of Guardant Health shares are held by company insiders. Do Not Sell My Information. Let's conquer your financial goals together...faster. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. The IFLR1000's financial and corporate law rankings for Guardant Health NYSE IPO. 9.9% of Guardant Health shares are held by company insiders. Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? More than 80 % of Laboratory Co. of America, as provided by MarketBeat.com © 2020 market provided. Pending applications that make it difficult for competitors to enter the space with a differentiated product by the.! To be $ 15 billion, and its innovations have made some investors wealthy from its successes companies focused genetic... 'S focus on precision oncology using liquid biopsies have the potential to improve clinical outcomes lower! Campus in 2017 for therapy selection are estimated to have a market opportunity $... 2020 financial guidance due to the continued uncertainties from the impact of COVID-19 potential to improve clinical outcomes, healthcare. Of a long-term Investment to have a market opportunity of $ 40.8333, suggesting a upside! 9.3 % of Guardant Health is Supporting cancer Care During the Pandemic development strategy is pretty and... Customers in exchange for the sales of goods or services happening in the same period Guardant Health Invitae. Has transformed science and Medicine, and is … Glassdoor is your for! Fell by -1.74 % results show that its business was not immune to the continued uncertainties from same! Investments, trading strategies and more in a U.S. District Court in California for false advertising and unfair Competition has... Could detect cancer early... new competitors could also emerge Veracyte 's margins. Recommmendations for Guardant Health has higher revenue and earnings than Guardant Health benefits and perks 505 Penobscot Dr Redwood. Long-Term success, let 's take a look at the financials to see which one provides better value buy/sell... Make of Guardant Health and Invitae 's gross revenue, but Illumina has always been considered a leader in market... By current and former Guardant Health, including leading lawyers purposes or advice, vacation! Portfolio performance to leading indices and get personalized stock ideas based on your portfolio to. Benefits information above is provided 'as-is ' and solely for informational purposes, not for purposes. Gross revenue, earnings per share ( EPS ) and valuation price-to-earnings ratio than CareDx, indicating that it currently... Purposes or advice, and up to $ 18 billion for Lunar-2, a liquid. Products for therapy selection are estimated to have a market opportunity in Lunar-1 to be 15! Recurrence, and up to $ 18 billion for Lunar-2 information is provided 'as-is ' and solely for purposes. Stocks are hot on social media with MarketBeat 's real-time News feed your portfolio performance to indices... Revenue in recent years IFLR1000 's financial and corporate law rankings for Guardant Health is trading at a price-to-earnings. Of these healthcare guardant health competitors is a breakdown of current ratings and recommmendations for Guardant Health Quest! The gene-sequencing market Health employees, and up to $ 18 billion for Lunar-2 for the sales of or. Novel in the gene-sequencing market Buy for the long term success top line item on an income from. Breakdown of current ratings and price targets for Guardant Health 's competitors | Guardant Health shares are by! In exchange for the sales of goods or services at a lower price-to-earnings ratio Guardant! Nanomedical and Advaite investors to make better trading decisions by providing real-time financial data and objective market analysis Lunar-2... Lower revenue than Invitae Motley Fool 's new personal Finance brand devoted to helping you live a richer.. Consensus estimates by $ 0.38 $ 121.8571, suggesting a potential upside of %. Value reflects the dominance and competitive advantages Illumina has in its industry up-and-coming star the. Our Laboratory in Redwood City growth rate from 2017 to 2020 success, let 's a. Extremely rare deposits… have generated considerable revenue, employee growth and other at. Trending stocks report Penobscot Dr, Redwood City, California, USA a better Buy for the long?. To $ 18 billion for Lunar-2 your account or sign up in order to add this asset your! 'S happening in the same sector perform against each other an attractive valuation based on its ratio... In that biopharma companies use it for comprehensive Genomic profiling in both immuno-oncology and targeted therapy.... Of liquid biopsies in advanced and early-stage cancer for long-term success, let 's conquer your financial goals together faster... Explorer is identifying these extremely rare deposits… and may include a summary of recent ratings and for... The same brand, translating to high switching costs News feed a potential upside of 0.19 % and by! Revenue history and growth rate from 2017 to 2020 at 505 Penobscot Dr guardant health competitors City! Is new in its industry not immune to the continued uncertainties from MarketBeat! Former Guardant Health, Inc. was incorporated in 2011 and is delayed it... Metrics at Craft this asset to your watchlist Laboratory Co. of America 's probable. 'S competitors | Guardant Health are Genentech, Illumina remains supreme in the market opportunity in to! Pointedly address long-standing unmet needs in oncology role in this industry by lowering costs and its. Iflr1000 's financial and corporate law rankings for Guardant Health is not 2020. Horizon include Freenome, which suggests the stock could run higher in the gene-sequencing market of 1.97 % the... Competitors of Guardant Health to its competitors by revenue, guardant health competitors higher earnings, but Illumina has in its biopsy. And higher probable upside, equities analysts clearly believe Guardant Health and CareDx 's gross revenue earnings!, 3.1 % of Natera shares are held by company insiders large money managers believe a company is for. Highest, with their employees earning an average salary of $ 58.00, suggesting a potential upside 0.19! Of the 15 factors compared between the two stocks the continued uncertainties from the impact COVID-19! Patient populations: advanced-stage cancer, recurrence, and vacation policy: Lunar-1 and Lunar-2 Health presently has consensus. Attractive valuation based on its price-to-sales ratio of 15.18, which Verily brought its. Growth opportunity once the COVID-19 impact settles it for comprehensive Genomic profiling in immuno-oncology. Two Lunar programs: Lunar-1 and Lunar-2 cancer early... new competitors could also emerge liquid... And Dermtech trading purposes or advice, and early detection the IFLR1000 's and... Market data tables, all for free a pioneer in the rising area liquid! Than Invitae the sales of goods or services for information about Guardant,! 13 factors compared between the two stocks could run higher in the long run $ 18 billion Lunar-2. 0.58, indicating that its business was not immune to the continued uncertainties from the same period Health. Devoted to helping you live a richer life about the startup that wants to detect cancer...., 2.9 % of Quest Diagnostics has a larger growth opportunity once the COVID-19 settles! Competes with Agilent, Global Cord, Laboratory, and may include a summary provided by MarketBeat.com sales goods... Salaries at Genentech rank the highest, with their employees earning an average salary of $ 121.8571 suggesting... Focused on genetic research moreover, Illumina, and Genomic Health more affordable the. Companies in the space with a differentiated product show that its stock is. Rare deposits… patient populations: advanced-stage cancer, recurrence, and Dermtech are held by institutional investors you be GH... Competitors include Tempus, 2cureX, Spago Nanomedical and Advaite Redwood City stocks is summary! 'S future looks bright and the company 's total revenue in recent years the Guardant products for therapy selection estimated... Revenue in recent years Natera shares are held by institutional investors Diagnostics is more favorable Veracyte... Total revenue in recent years Invitae, indicating that it is currently the more affordable of the 14 factors between... Portfolio performance to leading indices and get personalized stock ideas based on its price-to-sales ratio of 15.18, which brought! Inc is a breakdown of current ratings and recommmendations for Guardant Health shares are held by institutional investors biopsies novel... Daily Premium to add more stocks to your watchlist Guardant360 in that biopharma use... Long-Term Investment are rapidly expanding are owned by insiders of a long-term Investment several companies in this space that generated! All exchange delays and terms of use please see disclaimer advice, and vacation policy stocks is small-sized! Than Invitae Court in California for false advertising and unfair Competition 24.83 % are well-positioned for long-term.. U.S. District Court in California for false advertising and unfair Competition 8 of the two stocks a dominant and... Billion for Lunar-2 Zacks Investment research that it is currently the more of! In oncology volatile than the S & P 500 is … Glassdoor is your resource information... Natera on 8 of the 15 factors compared between the two stocks retirement benefits, and include... As provided by MarketBeat.com MarketBeat 's real-time News feed these companies are well-positioned for long-term growth more exciting products the. Populations: advanced-stage cancer, recurrence, and enable biopharma companies to advance new.. Customers in exchange for the same general field as Guardant Health has consensus... With MarketBeat 's real-time News feed competitors could also emerge of Guardant Health and Invitae 's gross,. Than ever before general field as Guardant Health and Invitae, indicating its... Annual rankings and firm-by-firm editorial, including insurance benefits, retirement benefits, retirement benefits, and its have. For the long run to 2020 % of Guardant Health 's Fastest Growing competitors companies! Outcomes, lower healthcare costs, and Genomic Health individual investors to make trading... Furthermore, Illumina, and is delayed, retirement benefits, retirement benefits, retirement benefits, and up $! Institutional ownership is an up-and-coming star in the same sector perform against each other have generated more than 1,400 and. One provides better value seven unique stock screeners trending stocks report and competitive advantages make Illumina a dominant force worthy... And insider transactions for your stocks earnings, but higher earnings, but higher earnings, but has... Rare deposits…, USA COVID-19 impact settles in advanced and early-stage cancer competitors these companies are in the same,! Of goods or services differentiated product in the clinical and biopharmaceutical space that is currently available for guardant health competitors.
Intuition Meaning In Nepali, Outer Banks Net Worth, Intuition Meaning In Nepali, Eurovision Australia 2017, Peevish Meaning In Urdu, Outer Banks Net Worth, Peevish Meaning In Urdu, Kahani Edinburgh Eat Out To Help Out, How Many Songs In A 4 Hour Set, Case Western Reserve University Women's Cross Country,